If Blarcamesine cannot gain approval in Europe it could be a long time before it gets approval in the US IMO. Meanwhile might 3-71 move ahead in Schizophrenia in a pivotal trial. And they have always said 3-71 had an application in Alzheimers. Interesting you chose Sarepta. I have some Capricor which is announcing some phase 3 DMD PUL and LVEF data expected this week or next. Biotechs can certainly be volatile!
Market Data 
Markets 
AI
